Plasma levels of the pro-inflammatory cytokine interleukin-6 (IL-6) on days 5–7 after symptom onset have previously been suggested to be a reliable biomarker in ischemic stroke and to correlate with brain infarct volume, stroke severity, and long-term outcome (14). The gene discussed is IL6; the disease is stroke disorder.